CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Mar. 27, 2019--
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today announced
the promotion of Ben Palleiko to Chief Business Officer in addition to
his current role as Chief Financial Officer, effective immediately.
“Ben has become an integral part of KalVista since joining over two
years ago to help establish us as a public company and drive our
financial strategy and growth,” said Andrew Crockett, Chief Executive
Officer of KalVista. “As we continue to grow and move into later stage
development this promotion is representative of Ben’s capabilities in a
larger role, as he will now also lead additional areas of increasing
importance including business development, commercial planning and
Mr. Palleiko joined KalVista as Chief Financial Officer in 2016. He has
over 20 years of experience in the industry, as both a senior life
sciences investment banker and Chief Financial Officer of several public
and private life sciences companies. He has raised more than $2 billion
in capital and completed over 50 financing and strategic transactions in
his career. Mr. Palleiko holds an MBA in Finance and a MA in
International Relations from the University of Chicago, and a BA in
Quantitative Economics from Tufts University. Prior to graduate school,
he served in the U.S. Navy as a Naval Aviator flying carrier-based jet
About KalVista Pharmaceuticals, Inc.
Pharmaceuticals, Inc. is a pharmaceutical company focused on the
discovery, development, and commercialization of small molecule protease
inhibitors for diseases with significant unmet need. The initial focus
is on inhibitors of plasma kallikrein, which is an important component
of the body’s inflammatory response and which, in excess, can lead to
increased vascular permeability, edema and inflammation. KalVista has
developed a proprietary portfolio of novel, small molecule plasma
kallikrein inhibitors initially targeting hereditary angioedema (HAE)
and diabetic macular edema (DME). The Company has created a structurally
diverse portfolio of oral plasma kallikrein inhibitors and is advancing
multiple drug candidates for HAE as well as DME. The Company has
selected KVD900 as its program to be advanced as an on-demand therapy
for HAE attacks and commenced a Phase 2 proof-of-concept study in HAE
patients in late 2018. In DME, KalVista’s most advanced program, an
intravitreally administered plasma kallikrein inhibitor known as KVD001,
is enrolling a Phase 2 clinical trial that is anticipated to complete in
the second half of 2019.
For more information, please visit www.kalvista.com.
This press release contains
"forward-looking" statements within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "goal," "seek," "believe," "project,"
"estimate," "expect," "strategy," "future," "likely," "may," "should,"
"will" and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, available funding, our
cash runway and future clinical trial timing and results. Further
information on potential risk factors that could affect our business and
its financial results are detailed in the annual report on Form 10-K
filed on July 30, 2018 and other reports as filed from time to time with
the Securities and Exchange Commission. We undertake no obligation to
publicly update any forward-looking statement, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190327005114/en/
Source: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc.
Corporate Communications & Investor Relations